Skip to content

Study · In vitro (cells) · 2018

5 results

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.

Al-Keilani MS, Alsmadi DH, Darweesh RS, Alzoubi KH

Clinical pharmacology : advances and applications5 Mar 2018Cited by 10 (Europe PMC)

PMID29551915 (opens in a new tab)PMCIDPMC5842772 (opens in a new tab)DOI10.2147/cpaa.s153780 (opens in a new tab)PepBankPUB-29551915
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In HCT-116 cells, pramlintide inhibited growth dose-dependently with an IC50 of 48.67 μg/mL.

    In plain wordsIn cells, pramlintide inhibited HCT-116 cancer cell growth with an IC50 of 48.67 μg/mL.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseHCT-116 growth inhibition
    Study

    n: not reported in source

    HCT-116 colorectal cancer cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    IC50
    48.67 μg/mL
    HCT-116 cells

    Source sentences

    Summary
    Pramlintide inhibited the growth of HCT-116 and HT-29 in a dose-dependent manner, with higher efficacy against the latter (IC50s; 48.67 and 9.10 μg/mL, respectively; p-value =0.013).
    1 context sentence
    Summary · context
    The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay.
  2. 02LabIn vitro (cells)Activity measurement

    In HT-29 cells, pramlintide inhibited growth dose-dependently with an IC50 of 9.10 μg/mL and greater efficacy than against HCT-116.

    In plain wordsIn cells, pramlintide inhibited HT-29 cancer cell growth more effectively than HCT-116 growth.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseHT-29 growth inhibition
    Study

    n: not reported in source

    HT-29 colorectal cancer cells
    Comparator
    HCT-116 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    IC50
    9.1 μg/mL
    HT-29 cells

    Source sentences

    Summary
    Pramlintide inhibited the growth of HCT-116 and HT-29 in a dose-dependent manner, with higher efficacy against the latter (IC50s; 48.67 and 9.10 μg/mL, respectively; p-value =0.013).
    1 context sentence
    Summary · context
    The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay.
  3. 03LabIn vitro (cells)Activity measurement

    In HCT-116 and HT-29 cells, adding pramlintide synergistically enhanced the antiproliferative effect of 5-fluorouracil.

    In plain wordsIn cells, adding pramlintide increased growth inhibition from 5-fluorouracil compared with the chemotherapy drug alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseSynergistic growth inhibition with 5-fluorouracil
    Study

    n: not reported in source

    HCT-116 and HT-29 colorectal cancer cells
    Comparator
    5-fluorouracil alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    5, 10, and 20 μg/mLAs given in this study.

    Source sentences

    Summary
    Moreover, the addition of 5, 10, and 20 μg/mL of pramlintide to HCT-116 and HT-29 with 5-fluorouracil, oxaliplatin, or irinotecan induced the antiproliferative effect synergistically (R>1.6, p-value <0.05).
    2 context sentences
    Summary · context
    Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50s.
    Summary · context
    The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay.
  4. 04LabIn vitro (cells)Activity measurement

    In HCT-116 and HT-29 cells, adding pramlintide synergistically enhanced the antiproliferative effect of oxaliplatin.

    In plain wordsIn cells, adding pramlintide increased growth inhibition from oxaliplatin compared with the chemotherapy drug alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseSynergistic growth inhibition with oxaliplatin
    Study

    n: not reported in source

    HCT-116 and HT-29 colorectal cancer cells
    Comparator
    Oxaliplatin alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    5, 10, and 20 μg/mLAs given in this study.

    Source sentences

    Summary
    Moreover, the addition of 5, 10, and 20 μg/mL of pramlintide to HCT-116 and HT-29 with 5-fluorouracil, oxaliplatin, or irinotecan induced the antiproliferative effect synergistically (R>1.6, p-value <0.05).
    2 context sentences
    Summary · context
    Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50s.
    Summary · context
    The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay.
  5. 05LabIn vitro (cells)Activity measurement

    In HCT-116 and HT-29 cells, adding pramlintide synergistically enhanced the antiproliferative effect of irinotecan.

    In plain wordsIn cells, adding pramlintide increased growth inhibition from irinotecan compared with the chemotherapy drug alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseSynergistic growth inhibition with irinotecan
    Study

    n: not reported in source

    HCT-116 and HT-29 colorectal cancer cells
    Comparator
    Irinotecan alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    5, 10, and 20 μg/mLAs given in this study.

    Source sentences

    Summary
    Moreover, the addition of 5, 10, and 20 μg/mL of pramlintide to HCT-116 and HT-29 with 5-fluorouracil, oxaliplatin, or irinotecan induced the antiproliferative effect synergistically (R>1.6, p-value <0.05).
    2 context sentences
    Summary · context
    Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50s.
    Summary · context
    The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.